OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers & Dementia is 65. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Speed of cognitive decline in biomarker stratified SCD subgroups	2522
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	1819
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum	1484
Automating the verbal paired associates test to assess memory remotely and at scale	1440
Regional correlation analysis between neuronal metabolism and synaptic density using [18F]FDG and [11C]UCB‐J	657
Using an entorhinal cortex‐based virtual reality navigation task to differentiate between individuals with and without subjective cognitive decline	453
A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau	369
Transient CSF1R Inhibition in the Early Stage of AD Retains Homeostatic Microglia with Reduced Inflammasomes and Increased autophagy in the 5XFAD Model	363
Short antibiotic treatment followed by regular administration of acid suppressant (proton pump inhibitor) reduce AB42 load in the brain and in the gut.	289
A Placebo‐Controlled Phase I Study in Healthy Subjects Assessing NVG‐291, which Targets CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ)	218
Neuropathology of a patient with AD treated with low doses of verubecestat	192
β‐secretase inhibition prevents structural spine plasticity deficits in AppNL‐G‐F mice	185
TREM2 Burden associates solely with Alzheimer’s Disease, and decreases the Chance to become a Centenarian	173
Whole‐exome sequencing of a Portuguese cohort of early‐onset Alzheimer’s disease implicates X‐linked lysosomal gene GLA	172
Association of Epigenetic Aging with Cognitive Aging in Diverse Hispanics/Latinos	170
Human postmortem studies as a driver of biomarker development	155
Exploring the role of brain DNA methylomic signatures on gene expression dynamics of frontotemporal lobar degeneration	150
Widespread transposable element dysregulation in human brains with Alzheimer’s disease	143
Validated, unified theory of Alzheimer Disease illuminates two essential research questions	135
Dynamic Light Scattering Spectroscopy as an Early Biomarker of Alzheimer’s Disease	130
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly	126
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	124
Addressing the gaps of the functional neuroimaging in young APOEe4 carriers: A systematic review and Graph Theoretical analysis of brain connectivity	123
Cerebral Small Vessel Disease and Gait Speed in Older Adults without Dementia	121
Development of an artificial intelligence approach that employs genomic and brain imaging features to improve the diagnosis of Alzheimer’s Disease (AD)	116

Automated word class and person usage metrics as markers of Alzheimer’s and frontotemporal dementia	113
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	108
Antagonistic Amyloid‐β and tau interactions with T1‐weighted/T2‐weighted magnetic resonance ratio in Alzheimer’s disesase continuum	105
White matter hyperintensities: A long‐term consequence of repetitive head impacts?	104
CASBA neurological assessment: Noninvasive EEG biomarkers classify amyloid‐PET, clinical diagnosis, cognitive dementia rating, and FCSRT free recall scores in patients with cognitive decline	101
Anti‐ulcer drug teprenone clinical trial	96
PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementia	95
WVE‐005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies	92
Synthetic FDG‐PET hypometabolism sensitivity validation in AD	89
Reconsideration of appropriate use criteria for amyloid PET based on real‐world experiences	88
CSF Biomarkers and [¹⁸F]flutemetamol PET‐Derived Centiloids in Patients with SCD or MCI	86
Cerebral perfusion and amyloidosis in the oldest‐old	85
Brain‐Penetrable Antibody Probes for in vivo Tau Imaging	85
TMS‐based measures of cortical excitability are related to distributed atrophy in early Alzheimer’s disease	83
Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction relat	83
PAS‐MCI: Design and rationale for a randomized controlled trial to enhance prefrontal cortical plasticity and working memory in individuals with amnestic mild cognitive impairment	80
A 5‐hydroxymethylation‐based clock derived from cell‐free DNA in blood reveals accelerated epigenetic aging in patients with Alzheimer’s disease	78
Combined effect of prebiotic and probiotic strains restores cognitive impairment via attenuating synaptosis in the hippocampus of mice fed with high fat diet and streptozotocin diabetes‐induced dement	78
A portable eye tracking experiment for the assessment of cognitive impairment in presymptomatic frontotemporal dementia	77
Observations on biomarkers in Roche Abeta‐targeting monoclonal antibody trials	76
Plasma biomarkers, memory impairment, and imaging measures of Alzheimer’s disease in American Indians	76
A retinal tauopathy with a characteristic molecular pattern points to the existence of a “Primary retinal tauopathy”	75
Automated lexical analysis of story recall in healthy controls	75
The App^NL‐G‐F/MAPT mouse model of Alzheimer’s Disease demonstrates increased levels of ptau217 in CSF, changes that correlate with increased cerebral p‐tau depositions	74
Determination of molecular chaperone levels in cerebrospinal fluids of Alzheimer’s patients	74
Explainable AI and its instantiation in Computational Pathology for a better understanding of Alzheimer’s disease	74
Plasma phosphorylated tau 181 and modifiable risk factors for dementia in a large scale cohort of Australian older adults	73
Perceptions of Shared decision making in cognitive impairment of LTC recipients	73
Baseline and Six‐Month Actigraphy and Sleep‐monitoring Devices Help Differentiate Between Alzheimer’s Disease and Dementia with Lewy Bodies	73
Elderly Role Performance Occupational Therapy	73
Longitudinal patterns of behavioral and psychological symptoms of dementia in community‐dwelling older people	72
Exploring Narrative Identity via Linguistic Positioning in the Context of Alzheimer’s Dementia Risk Prediction – an Ethical and Linguistic Analysis	72
Impact of the COVID‐19 Pandemic on Patients with Dementia or Parkinson’s Disease and their Caregivers in Lima, Peru	70
Tolerability and Likeability of a Cognitive Training Program in an Outpatient Memory Care Clinic	69
A 10‐minute Digitally Administered and Scored Neuropsychological Protocol Assessing Executive Control and Episodic Memory	69
A Study of Factors Influencing Quality of Life among Community Dwelling Elderly in Korean Urban Community	69
Decline in everyday functioning in relation to cerebral tau burden across the clinical spectrum of Alzheimer’s disease	68
Identification of objective cognitive decline in preclinical Alzheimer’ disease	67
Unsupervised Learning‐based Drug Repositioning for Alzheimer’s Disease Targeting Brain Cell Type Specific Genetic Subtypes	65
Comparing associations of Alzheimer’s disease plasma biomarkers with remote self‐administered cognitive measures versus in‐person neuropsychological tests	65